dc.contributor.author |
Garcia-Recio, M. |
|
dc.contributor.author |
Martinez-Serra, J. |
|
dc.contributor.author |
Mestre, F. |
|
dc.contributor.author |
Bento, L. |
|
dc.contributor.author |
Gines, J. |
|
dc.contributor.author |
Ramos, R. |
|
dc.contributor.author |
Daumal, J. |
|
dc.contributor.author |
López, P. |
|
dc.contributor.author |
Sampol, A. |
|
dc.contributor.author |
Gutierrez, A. |
|
dc.date.accessioned |
2019-09-24T06:45:05Z |
|
dc.date.available |
2019-09-24T06:45:05Z |
|
dc.identifier.uri |
http://hdl.handle.net/11201/149933 |
|
dc.description.abstract |
Abstract: Hodgkin lymphoma (HL) represents ~11% of all lymphoma cases. This disease occurs in young adults, but also affects people over 55 years of age. Despite the fact that >80% of all newly diagnosed patients under 60 will achieve a sustained complete response (CR), 5%-10% of HL patients are refractory to initial treatment and 10%-30% of patients will eventually relapse after an initial CR. The treatment recommendation for primary refractory or relapsed HL patients is salvage therapy followed by high-dose chemotherapy and autologous stem cell transplantation. Following this approach, a significant part will still relapse at any moment. Thus, further research and new drugs or combinations are required. Overexpression of COX-2 has been associated with poor prognosis in relapse/refractory HL patients, so it could be a potential therapeutic target in HL. For this purpose, several drugs may have a role: specific COX-2 inhibitors such as celecoxib or other anti-inflammatory drugs such as lenalidomide may further inhibit lipopolysaccharide-mediated induction of COX-2. Moreover, lenalidomide and COX-2 inhibitors (celecoxib) have been tested in solid tumors with encouraging results. We present a case of a young female diagnosed with a heavily pretreated HL nodular sclerosis subtype who, after failing six treatment lines, only achieved clinical and radiological CR after six cycles of lenalidomide/celecoxib that resulted in an event-free survival of 22 months. We explain the rationale of using this chemotherapy regimen and our patient follow-up. |
|
dc.format |
application/pdf |
|
dc.relation.isformatof |
https://doi.org/10.2147/OTT.S175016 |
|
dc.relation.ispartof |
Oncotargets And Therapy, 2018, vol. 11, p. 6599-6603 |
|
dc.rights |
, 2018 |
|
dc.subject.classification |
616 - Patologia. Medicina clínica. Oncologia |
|
dc.subject.other |
616 - Pathology. Clinical medicine |
|
dc.title |
Complete response associated with lenalidomide and celecoxib in a case of primary refractory Hodgkin lymphoma. |
|
dc.type |
info:eu-repo/semantics/article |
|
dc.date.updated |
2019-09-24T06:45:05Z |
|
dc.rights.accessRights |
info:eu-repo/semantics/openAccess |
|
dc.identifier.doi |
https://doi.org/10.2147/OTT.S175016 |
|